Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study.

Shilong Deng, Xue Yan, Ying Peng, Lijun Zhu, Yongshi Shen, Wenmin Ying, Yuanji Xu, Zhichao Fu

Abstract read

In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shilong DengDepartment of Radiotherapy, Fuzong Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou 350025, China.ORCID 0009-0007-4753-5255

Xue YanDepartment of Radiotherapy, Fuzong Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou 350025, China.

Ying PengDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.

Lijun ZhuDepartment of Radiotherapy, Fuzong Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou 350025, China.

Yongshi ShenDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.

Wenmin YingDepartment of Radiotherapy, Fuding Hospital, Fuding 355200, China.

Yuanji XuDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.ORCID 0000-0002-7194-0433

Zhichao FuDepartment of Radiotherapy, Fuzong Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou 350025, China.

Funding

Wu Jieping Medical Foundation No. 320.6750.2024-16-28

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immunotherapylocally advanced resectable esophageal squamous cell carcinomaneoadjuvant chemoradiotherapysurvival

Identifiers

PMID41514663

DOI10.3390/cancers18010155

PMCPMC12784656

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.